UCB's Global Corporate Website

Open for business, open to innovation

Posted by
Scott Fleming, UK Communications
Collaboration, cooperation, open innovation: much has been said and written about the need for industry and academia to work together to unlock the full potential of scientific knowledge.

At UCB, we do more than talk about open innovation – we are living it.

We are opening our new cutting-edge 'robotic lab' to scientists. Through our new Technology Platform Access Programme (TPAP), academic and research groups can work with our custom-built automated antibody discovery platform which is designed to speed up our drug development work and increase our capacity to bring new therapies to patients.

UCB is actively seeking collaborators interested in the opportunity to participate in our TPAP and work together with us on the discovery of new medicines.

A new sub-section on our website explains how researchers from outside our company can tap into this technology and work with us to improve patient outcomes.

The site explains our technology, how it enhances our capabilities, and how to apply to the antibody programme. There is even a section which answers Frequently Asked Questions (FAQs).

Patients with severe diseases deserve the best access to innovation no matter where it comes from.They want therapies that meet their unmet medical need.  This is the spirit behind our decision to launch this programme.

Learn more about the Technology Platform Access Programme.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.


Enter the characters shown in the image.